Parnell Pharm Ord (PARN) 1.62 $PARN Riviera Hires Tech

New Post Public Reply Private Reply Replies (0) Message Board

Sep 23, 2016 at 9:11 AM

Parnell Pharm Ord (PARN) 1.62 $PARN

Riviera Hires Tech Entrepreneur Will Hunsinger as COO
GlobeNewswire - Wed Aug 10, 12:00PM CDT
Riviera, a tech-enabled recruiting firm providing services to tech companies seeking the best engineering talent, has announced the appointment of Will Hunsinger as chief operating officer. An experienced entrepreneur who has co-founded and held the title of CEO at several startups, Hunsinger is expressly qualified to assist Riviera with its mission to redefine the recruiting industry using technology and data science.
PARN: 1.62 (+0.08)

Parnell Pharmaceuticals Holdings Ltd Announces Financial Results for the Six-Month Period Ended June 30, 2016
GlobeNewswire - Thu Aug 04, 6:01AM CDT
Parnell Pharmaceuticals Holdings Ltd (NASDAQ

ARN), a fully integrated, commercial-stage pharmaceutical company focused on developing, manufacturing and marketing innovative animal health solutions, today announced financial results for the first six months of 2016 including; strong revenue growth of 67%; the commencement of contract manufacturing revenues; the upcoming US launch of two new companion animal products, Luminous (TM) and Reviderm(TM); and the commencement of several new studies for PAR121, PAR122 and Zydax for cats.
PARN: 1.62 (+0.08)

Parnell Pharmaceuticals Holdings Ltd Announces Contract Manufacturing Agreement with Merial
GlobeNewswire - Tue May 31, 3:05PM CDT
Parnell Pharmaceuticals Holdings Ltd (NASDAQ

ARN), a fully integrated, commercial-stage pharmaceutical company focused on developing, manufacturing and marketing innovative animal health solutions, today announced the commencement of a Contract Manufacturing Agreement with Merial, the animal health division of Sanofi.
PARN: 1.62 (+0.08)

Parnell Pharmaceuticals Holdings Ltd Announces Pricing of an Underwritten Public Offering of Common Stock
GlobeNewswire - Thu May 12, 6:00AM CDT
Parnell Pharmaceuticals Holdings Ltd (NASDAQ

ARN), a fully integrated, commercial-stage pharmaceutical company focused on developing, manufacturing and marketing innovative animal health solutions, today announced the pricing of an underwritten public offering of 2,550,000 of its ordinary shares for $4,207,500. In addition, Parnell has granted the underwriters a 30-day option to purchase, from time to time, in whole or in part, up to an aggregate of 382,500 additional ordinary shares at the public offering price, less underwriting discounts and commissions. The offering is expected to close on May 17, 2016, subject to customary closing conditions.
PARN: 1.62 (+0.08)

Parnell Pharmaceuticals Holdings Ltd Announces First Quarter Business Update
GlobeNewswire - Fri Apr 22, 6:00AM CDT
Parnell continues to grow rapidly with revenue increasing 43% for the three months ended March 31, 2016
PARN: 1.62 (+0.08)

Parnell Pharmaceuticals Holdings signs USD15m agreement Lincoln Park Captial Fund
M2 - Thu Jan 21, 3:41AM CST
Pharmaceutical company Parnell Pharmaceuticals Holdings (NasdaqGM

ARN) reported on Wednesday that it has entered into a USD15m share purchase agreement with Lincoln Park CapitalFund.
PARN: 1.62 (+0.08)

UPDATE -- Parnell Pharmaceuticals Holdings Ltd Announces Agreement With Lincoln Park Capital Fund to Purchase Ordinary Shares
GlobeNewswire - Wed Jan 20, 12:01PM CST
Parnell Pharmaceuticals Holdings Ltd. ("Parnell" or "Company"

(NASDAQ

ARN), a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions, today announced that it has entered into a share purchase agreement with Lincoln Park Capital Fund, LLC, a Chicago-based institutional investor ("Lincoln Park"

. The agreement is structured as an equity commitment and enables Parnell to elect entirely at its discretion to sell up to 35,000 shares on any one day to Lincoln Park and under certain circumstances can elect to sell up to 55,000 shares on any one day.
PARN: 1.62 (+0.08)

Parnell Pharmaceuticals Holdings Ltd Announces Agreement With Lincoln Park Captial Fund to Purchase Ordinary Shares
GlobeNewswire - Tue Jan 19, 4:16PM CST
Parnell Pharmaceuticals Holdings Ltd. ("Parnell" or "Company"

(NASDAQ

. The agreement is structured as an equity commitment and enables Parnell to elect entirely at its discretion to sell up to 35,000 shares on any one day to Lincoln Park and under certain circumstances can elect to sell up to 55,000 shares on any one day.
PARN: 1.62 (+0.08)

Parnell Pharmaceuticals Holdings Ltd to Present at Biotech Showcase Conference in San Francisco
GlobeNewswire - Mon Jan 11, 9:02AM CST
Parnell Pharmaceuticals Holdings Ltd (Nasdaq

ARN), a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions, today announced that Robert Joseph, President and Chief Executive Officer, will be presenting at the Biotech Showcase Conference in San Francisco on Monday, January 11, 2015 at 11:30 AM PST.
PARN: 1.62 (+0.08)

Parnell Appoints Ellen B. Richstone and Dr. David K. Rosen to the Board of Directors
GlobeNewswire - Thu Dec 17, 10:00AM CST
Parnell Pharmaceuticals Holdings Ltd (Nasdaq

ARN), a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions, today announced the appointment of Ellen B. Richstone and Dr. David K. Rosen to its Board of Directors. The appointments increase the Board to six directors, and the number of independent directors to three.
PARN: 1.62 (+0.08)

Parnell Pharmaceuticals Holdings Ltd to Present at Jefferies 2015 Global Healthcare Conference in London
GlobeNewswire - Wed Nov 18, 7:00AM CST
Parnell Pharmaceuticals Holdings Ltd (NASDAQ

ARN), a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions, today announced that Robert Joseph, President and Chief Executive Officer, will be presenting at the Jefferies 2015 Global Healthcare Conference in London on Wednesday, November 18, 2015 at 5:20 p.m. GMT.
PARN: 1.62 (+0.08)

Parnell to Report Financial Results for the Nine Months Ended September 30, 2015 on October 21, 2015
GlobeNewswire - Fri Oct 09, 12:00PM CDT
Parnell Pharmaceuticals Holdings Ltd. (NASDAQ

ARN), a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions, announced today that on October 21, 2015 at 7:00 a.m. ET it will report financial results for the nine-month period ended September 30, 2015.
PARN: 1.62 (+0.08)

Parnell Pharmaceuticals Holdings Ltd to Present at Ladenburg Thalmann 2015 Healthcare Conference
GlobeNewswire - Mon Sep 28, 12:54PM CDT
Parnell Pharmaceuticals Holdings Ltd (NASDAQ

ARN), a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions, today announced that Robert Joseph, President and Chief Executive Officer, will be presenting at the Ladenburg Thalmann 2015 Healthcare Conference in New York on Tuesday, September 29, 2015 at 2:30 PM ET.
PARN: 1.62 (+0.08)

Parnell names Peter A. Croden to board
M2 - Tue Aug 11, 3:16AM CDT
Pharmaceutical company Parnell Pharmaceuticals Holdings (NasdaqGM

ARN) disclosed on Monday the addition of Peter A. Croden to its board of directors, including its Audit and Compensation Committees.
PARN: 1.62 (+0.08)

Parnell Appoints Peter A. Croden to Board of Directors
GlobeNewswire - Mon Aug 10, 1:00PM CDT
Appointment increases Board to seven members, four of whom are independent
PARN: 1.62 (+0.08)

Parnell to Report Financial Results for the Six Months Ended June 30, 2015 on August 11, 2015
GlobeNewswire - Wed Jul 29, 3:00PM CDT
Parnell Pharmaceuticals Holdings Ltd. (NASDAQ

ARN), a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions, announced today that on August 11, 2015 at 7:00 a.m. ET it will report financial results for the six-month period ended June 30, 2015.
PARN: 1.62 (+0.08)

Parnell Pharmaceuticals Holdings Ltd Investor Day Highlights
GlobeNewswire - Thu Jun 18, 10:00AM CDT
Parnell Pharmaceuticals Holdings Ltd (Nasdaq

ARN), a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions, released highlights from its inaugural Investor Day held today in New York City. The day was centered on new trial results for Zydax, Parnell's osteoarthritis (OA) therapeutic being developed for dogs and horses, which demonstrated a significant improvement in clinical signs of osteoarthritis in dogs in a pivotal clinical efficacy trial. Management also provided details of its U.S. and European commercialization plans for Zydax and Glyde(R) - Parnell's nutraceutical product for OA. The presentation included guidance for the company's companion and production animal businesses and product pipeline discussion. Noted industry experts provided insights into trends and emerging markets in the animal healthcare industry.
PARN: 1.62 (+0.08)

Parnell Pharmaceuticals Holdings Ltd Announces $11 Million Secured Term Loan Facility
GlobeNewswire - Thu Jun 18, 6:30AM CDT
Parnell Pharmaceuticals Holdings Ltd (Nasdaq

ARN), a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions, today announced that it has entered into a non-dilutive $US11 million term loan agreement with MidCap Financial. The Company intends to use the loan proceeds for the expansion of its Companion Animal sales team in the US and general company purposes.
PARN: 1.62 (+0.08)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

FC2 Condom Educates NYC on Health and Wellness

Union Square Becomes a Hub of Interactivity The heart of NYC pulsed with purpose as FC2 Female Condom set up shop in Union Square, using the iconic location as a stage for a different kind of celebration. Clear Future, the manufacturer behind FC2, marked Global Female Condom Day with an event unlike any other. It wasn't just about the product—it was a call to educate...

TGI Fridays Unveils New 3 For All Menu Options

Hedging Bets on New Dining Strategies Oh, the restaurant battlefield—where one day you're the toast of the town, and the next, you're hustling to keep those seats filled. TGI Fridays, a name as synonymous with casual eats as long as I’ve been in this game, is rolling the dice with a new offering dubbed '3 For All.' Doesn't sound like your average meal deal either....

BMAP Expands: Bridging Borders in Legal Advocacy

Breaking Down BMAP's Unique Approach Just when you thought you've seen it all, along comes LMU Loyola Law School swinging the doors wide open with their Binational Migrant Advocacy Project, or as we’re affectionately calling it, BMAP. It's a mouthful, sure, but ain't it something? This project isn't just another feather in academia's cap—it's a relentless counterpunch...

Paula's Choice Elevates Skincare Game with New Campaign

Strategy Meets Skincare: Paula's Choice in the Spotlight Catch this: Paula's Choice just dropped a moisturizer, but it ain't just lotion. No, the Pro-Collagen Peptide Plumping Intensive Moisturizer is here with a punch. And they've got Hannah Waddingham, of 'Ted Lasso' fame, fronting a campaign that screams confidence. Now, that's a way to announce your move at the...

CSS Revamps Identity, Emphasizing Senior Living Tech

CSS Takes a Bold Step with a Fresh Brand Identity Every now and then, you see a company shake off the old coat and put on a polished new one. That's what CSS is doing with its updated brand, staking its claim as a heavyweight tech player in the senior living sector. No small feat, given the challenges stacked against these aging communities—tasked with keeping...

Orthopedic Expert Highlighting Midwest Pain Access Gaps

Over in the vast sprawl of rolling plains and prairie winds, folks in the Upper Midwest are grappling with an ironic reality. As technological advancements blaze trails, people suffering from vertebrogenic pain are finding themselves up against a wall of limited access to specialized care. We’ve got Dr. James T. Brunz, the man of the hour, one of only about 15 Intracept...

Robotics in Cleaning: 2026 Sees Double Adoption Rates

Cleaning Industry Eyes Robotic Solutions Amid Labor Squeeze In a twist that's got industry veterans nodding knowingly, the cleaning industry is tipping towards automation. The recent 2026 Building Service Contractor Market Study reveals a massive leap: 32% of building service contractors (BSCs) plan to embrace robotic floor equipment in the coming year. That's a...

TWP & Commbi Unveil Exclusive Pony Clog Collaboration

A Fusion of Fashion and Functionality Walk down the streets of New York or hustle your way through an airport without worrying about your footwear weighing you down. That's the promise coming from the fresh alliance between TWP and Commbi with their new Pony Clog Collaboration. A blend of high fashion and everyday utility, these clogs aren't just keeping up with the...

Perk's U.S. Expansion: A Bold Move in Spend Control

Perk Aims for U.S. Growth: Will It Pay Off? Amidst the cacophony of market chatter, Perk's announcement to bring its spend platform stateside is echoing louder than usual. This move is not just another step in its expansion but rather a leap considering the competition and market needs. In Europe, where they've already captured a chunk of the market with their Travel and...

Inovonics Duress Card Enhances Safety for K-12 and Beyond

A New Dawn for Safety in Schools and More It's about time we talk about something more substantial than just beefing up security cameras or tightening door locks. Real-world problems require nimble solutions, and that's where Status Solutions steps in with the Inovonics Duress Card. It's not just another gadget; it's a lightweight, wrist-mounted lifeline designed to say,...